Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus

Abstract

We report on a 23-year-old Japanese female with a 13-year history of systemic lupus erythematosus (SLE), and two episodes of deterioration followed by treatment with high dose prednisolone. Although she had been recently treated with prednisolone (12.5 mg daily), her liver function became worse in July 1998. Results of a liver biopsy revealed multi-focal hepatic cell death in a severe fatty liver, without any inflammatory cell invasion. The biopsy also showed a positive TUNEL (Tdt-catalysed DNA nick end labelling) reaction indicating apoptosis. Her liver function recovered rapidly following steroid pulse therapy. Serum soluble Fas ligand (sFasL) was found to be elevated to a concentration of 0.395 ng/ml at the time of liver damage, but was less than 0.03 ng/ml before liver damage and after prednisolone treatment. The liver damage in this case appeared to be involved with apoptosis induced by sFasL. Although hepatitis associated with SLE is rare, apoptosis directly related to elevated sFasL levels might cause this complication.

Keywords

systemic lupus erythematosus lupus hepatitis apoptosis programmed cell death soluble Fas ligand

Get full access to this article

View all access options for this article.

References

Hayashi N , Mita E . Fas system and apoptosis in viral hepatitis . J Gastroenterol Hepatol 1997; 12 (Suppl.): S223–S226 .

Seino K , Kayagaki N , Takeda K et al. Contribution of Fas ligand to T cell-mediated hepatic injury in mice . Gastroenterology 1997; 113: 1315–1322 .

Gong WR , Pecci A , Roth S et al. Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand . Hepatology 1998; 28: 492–502 .

Feldmann G , Lamboley C , Moreau A , Bringuier A . Fas-mediated apoptosis of hepatic cells . Biomed Pharmacother 1998; 52: 378–385 .

Shiota G , Oyama K , Noguchi N et al. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis . Res Comm Mol Pathol Pharmacol 1998; 101: 3–12 .

Kovacs B , Liossis SNC , Dennis GJ , Tsokos GC . Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus . Autoimmunity 1997; 25: 213–221 .

McNally J , Yoo DH , Drappa J et al. Fas ligand expression and function in systemic lupus erythematosus . J Immunol 1997; 159: 4268–4636 .

Atsumi T , Sagawa A , Jodo S et al. Severe hepatic involvement without inflammatory changes in systemic lupus erythematosus: report of two cases and review of literature . Lupus 1995; 4: 225–228 .

Ksontini R , Colaviovanni DB , Josephs MD et al. Disparate roles for TNF-a and Fas ligand in concanavalin A-induced hepatitis . J Immunol 1998; 160: 4082–4089 .

10.

Jodo S , Kobayashi S , Kayagaki N et al. Serum level of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases . Clin Exp Immunol 1997; 107: 89–95 .

11.

Rumore PM , Steinman CR . Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone . J Clin Invest 1990; 86: 69–74 .